{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:34:59Z","timestamp":1777599299426,"version":"3.51.4"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000054","name":"U.S. Department of Health & Human Services | NIH | National Cancer Institute","doi-asserted-by":"publisher","award":["R44CA221539"],"award-info":[{"award-number":["R44CA221539"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"U.S. Department of Health & Human Services | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R43AR075438"],"award-info":[{"award-number":["R43AR075438"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Commercial development of gene therapeutics often requires transitioning to human payload genes as initial proof-of-concept studies in animal models often use taxa-specific orthologs. Such transitions also provide opportunities to address potential secondary structure and immune-related subsequences as with human Smad7 cDNA, which was optimized by removing several repeats, potential hairpins and negative\n                    <jats:italic>cis<\/jats:italic>\n                    elements. Thermodynamic modeling at or above minimal free energy states revealed substantial improvements in secondary structure with fewer hairpins and improved diversity scores. Serotype 6 adeno-associated viral vectors with optimized human Smad7 (AVGN7.2) expression constructs were equally or more effective than those with wild-type mouse Smad7 in stimulating skeletal muscle hypertrophy and enhancing isometric torque of hind-limb dorsiflexor muscles in vivo. In murine models of Duchenne Muscular dystrophy, where deficits in muscle mass and disproportionate declines in force are pathognomonic, AVGN7.2 proportionally increased muscle mass and isometric torque while normalizing contractile kinetics. Such improvements occurred without deleterious impacts on serum creatine kinase, fibrosis or myofiber central nucleation. These data suggest that AVGN7.2 is capable of enhancing dystrophic muscle function without exacerbating muscle degeneration. Although these functional effects were partial, they resembled those of several dystrophin-targeting drugs and suggest that combinatorial approaches may safely yield further benefit.\n                  <\/jats:p>","DOI":"10.1038\/s41434-025-00583-0","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:34:42Z","timestamp":1764081282000},"page":"1-11","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Codon-optimized human Smad7 gene therapy enhances skeletal muscle mass and function in a murine model of Duchenne muscular dystrophy"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0751-1105","authenticated-orcid":false,"given":"Buel D.","family":"Rodgers","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher W.","family":"Ward","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"583_CR1","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1007\/s40259-018-0261-x","volume":"32","author":"VP Mauro","year":"2018","unstructured":"Mauro VP. Codon optimization in the production of recombinant biotherapeutics: potential risks and considerations. BioDrugs. 2018;32:69\u201381.","journal-title":"BioDrugs"},{"key":"583_CR2","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1016\/j.jmb.2020.01.011","volume":"432","author":"J Kames","year":"2020","unstructured":"Kames J, Alexaki A, Holcomb DD, Santana-Quintero LV, Athey JC, Hamasaki-Katagiri N, et al. TissueCoCoPUTs: novel human tissue-specific codon and codon-pair usage tables based on differential tissue gene expression. J Mol Biol. 2020;432:3369\u201378.","journal-title":"J Mol Biol"},{"key":"583_CR3","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s11033-021-06749-4","volume":"49","author":"ST Parvathy","year":"2022","unstructured":"Parvathy ST, Udayasuriyan V, Bhadana V. Codon usage bias. Mol Biol Rep. 2022;49:539\u201365.","journal-title":"Mol Biol Rep"},{"key":"583_CR4","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1002\/bit.28412","volume":"120","author":"Q Fu","year":"2023","unstructured":"Fu Q, Polanco A, Lee YS, Yoon S. Critical challenges and advances in recombinant adeno-associated virus (rAAV) biomanufacturing. Biotechnol Bioeng. 2023;120:2601\u201321.","journal-title":"Biotechnol Bioeng"},{"key":"583_CR5","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1210\/endrev\/bnab030","volume":"43","author":"BD Rodgers","year":"2022","unstructured":"Rodgers BD, Ward CW. Myostatin\/activin receptor ligands in muscle and the development status of attenuating drugs. Endocr Rev. 2022;43:329\u201365.","journal-title":"Endocr Rev"},{"key":"583_CR6","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073\u201380.","journal-title":"Mol Ther"},{"key":"583_CR7","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1016\/j.ymthe.2006.01.014","volume":"13","author":"J Seppen","year":"2006","unstructured":"Seppen J, Bakker C, de Jong B, Kunne C, van den Oever K, Vandenberghe K, et al. Adeno-associated virus vector serotypes mediate sustained correction of bilirubin UDP glucuronosyltransferase deficiency in rats. Mol Ther. 2006;13:1085\u201392.","journal-title":"Mol Ther"},{"key":"583_CR8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-81046-5","volume":"11","author":"D Weber-Adrian","year":"2021","unstructured":"Weber-Adrian D, Kofoed RH, Silburt J, Noroozian Z, Shah K, Burgess A, et al. Systemic AAV6-synapsin-GFP administration results in lower liver biodistribution, compared to AAV1&2 and AAV9, with neuronal expression following ultrasound-mediated brain delivery. Sci Rep. 2021;11:1934.","journal-title":"Sci Rep"},{"key":"583_CR9","doi-asserted-by":"publisher","first-page":"4919","DOI":"10.1016\/j.cell.2021.08.028","volume":"184","author":"M Tabebordbar","year":"2021","unstructured":"Tabebordbar M, Lagerborg KA, Stanton A, King EM, Ye S, Tellez L, et al. Directed evolution of a family of AAV capsid variants enabling potent muscle-directed gene delivery across species. Cell. 2021;184:4919\u201338.e22.","journal-title":"Cell"},{"key":"583_CR10","doi-asserted-by":"crossref","unstructured":"Agarwal S. High-dose AAV gene therapy deaths. Nat Biotechnol. 2020;38:910.","DOI":"10.1038\/s41587-020-0642-9"},{"key":"583_CR11","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1089\/hum.2020.182","volume":"31","author":"JM Wilson","year":"2020","unstructured":"Wilson JM, Flotte TR. Moving forward after two deaths in a gene therapy trial of myotubular myopathy. Hum Gene Ther. 2020;31:695\u20136.","journal-title":"Hum Gene Ther"},{"key":"583_CR12","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1089\/hum.2017.158","volume":"29","author":"JW Maricelli","year":"2018","unstructured":"Maricelli JW, Bishaw YM, Wang B, Du M, Rodgers BD. Systemic SMAD7 gene therapy increases striated muscle mass and enhances exercise capacity in a dose-dependent manner. Hum Gene Ther. 2018;29:390\u20139.","journal-title":"Hum Gene Ther"},{"key":"583_CR13","doi-asserted-by":"publisher","first-page":"348ra98","DOI":"10.1126\/scitranslmed.aac4976","volume":"8","author":"CE Winbanks","year":"2016","unstructured":"Winbanks CE, Murphy KT, Bernardo BC, Qian H, Liu Y, Sepulveda PV, et al. Smad7 gene delivery prevents muscle wasting associated with cancer cachexia in mice. Sci Transl Med. 2016;8:348ra98.","journal-title":"Sci Transl Med"},{"key":"583_CR14","doi-asserted-by":"publisher","first-page":"10792","DOI":"10.1074\/jbc.M115.713487","volume":"291","author":"S Aykul","year":"2016","unstructured":"Aykul S, Martinez-Hackert E. Transforming growth factor-beta family ligands can function as antagonists by competing for type II receptor binding. J Biol Chem. 2016;291:10792\u2013804.","journal-title":"J Biol Chem"},{"key":"583_CR15","doi-asserted-by":"publisher","first-page":"21037","DOI":"10.1074\/jbc.M110.114959","volume":"285","author":"D Sako","year":"2010","unstructured":"Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R, Maniatis S, et al. Characterization of the ligand binding functionality of the extracellular domain of activin receptor type IIb. J Biol Chem. 2010;285:21037\u201348.","journal-title":"J Biol Chem"},{"key":"583_CR16","doi-asserted-by":"crossref","unstructured":"Arnett AL, Konieczny P, Ramos JN, Hall J, Odom G, Yablonka-Reuveni Z, et al. Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Mol Ther Methods Clin Dev. 2014;1:14038.","DOI":"10.1038\/mtm.2014.38"},{"key":"583_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms14454","volume":"8","author":"NE Bengtsson","year":"2017","unstructured":"Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, et al. Muscle-specific CRISPR\/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nat Commun. 2017;8:14454.","journal-title":"Nat Commun"},{"key":"583_CR18","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.omtm.2019.11.015","volume":"17","author":"BD Rodgers","year":"2020","unstructured":"Rodgers BD, Bishaw Y, Kagel D, Ramos JN, Maricelli JW. Micro-dystrophin gene therapy partially enhances exercise capacity in older adult mdx mice. Mol Ther Methods Clin Dev. 2020;17:122\u201332.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"583_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-3810-0_1","volume":"1460","author":"JA Call","year":"2016","unstructured":"Call JA, Lowe DA. Eccentric contraction-induced muscle injury: reproducible, quantitative, physiological models to impair skeletal muscle\u2019s capacity to generate force. Methods Mol Biol. 2016;1460:3\u201318.","journal-title":"Methods Mol Biol"},{"key":"583_CR20","doi-asserted-by":"publisher","first-page":"ra56","DOI":"10.1126\/scisignal.2002829","volume":"5","author":"RJ Khairallah","year":"2012","unstructured":"Khairallah RJ, Shi G, Sbrana F, Prosser BL, Borroto C, Mazaitis MJ, et al. Microtubules underlie dysfunction in Duchenne muscular dystrophy. Sci Signal. 2012;5:ra56.","journal-title":"Sci Signal"},{"key":"583_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13395-015-0064-4","volume":"5","author":"M Riaz","year":"2015","unstructured":"Riaz M, Raz Y, Moloney EB, van Putten M, Krom YD, van der Maarel SM, et al. Differential myofiber-type transduction preference of adeno-associated virus serotypes 6 and 9. Skelet Muscle. 2015;5:37.","journal-title":"Skelet Muscle"},{"key":"583_CR22","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.ymthe.2019.01.002","volume":"27","author":"JN Ramos","year":"2019","unstructured":"Ramos JN, Hollinger K, Bengtsson NE, Allen JM, Hauschka SD, Chamberlain JS. Development of novel micro-dystrophins with enhanced functionality. Mol Ther. 2019;27:623\u201335.","journal-title":"Mol Ther"},{"key":"583_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/j.1365-2990.1988.tb00866.x","volume":"14","author":"GR Coulton","year":"1988","unstructured":"Coulton GR, Morgan JE, Partridge TA, Sloper JC. The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol Appl Neurobiol. 1988;14:53\u201370.","journal-title":"Neuropathol Appl Neurobiol"},{"key":"583_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2021.771499","volume":"12","author":"L Kiriaev","year":"2021","unstructured":"Kiriaev L, Kueh S, Morley JW, North KN, Houweling PJ, Head SI. Lifespan analysis of dystrophic mdx fast-twitch muscle morphology and its impact on contractile function. Front Physiol. 2021;12:771499.","journal-title":"Front Physiol"},{"key":"583_CR25","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/j.1469-7793.2001.00591.x","volume":"535","author":"GS Lynch","year":"2001","unstructured":"Lynch GS, Hinkle RT, Chamberlain JS, Brooks SV, Faulkner JA. Force and power output of fast and slow skeletal muscles from mdx mice 6-28 months old. J Physiol. 2001;535:591\u2013600.","journal-title":"J Physiol"},{"key":"583_CR26","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1038\/mt.2010.308","volume":"19","author":"MA Goncalves","year":"2011","unstructured":"Goncalves MA, Janssen JM, Nguyen QG, Athanasopoulos T, Hauschka SD, Dickson G, et al. Transcription factor rational design improves directed differentiation of human mesenchymal stem cells into skeletal myocytes. Mol Ther. 2011;19:1331\u201341.","journal-title":"Mol Ther"},{"key":"583_CR27","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1089\/hum.2008.197","volume":"20","author":"M Martari","year":"2009","unstructured":"Martari M, Sagazio A, Mohamadi A, Nguyen Q, Hauschka SD, Kim E, et al. Partial rescue of growth failure in growth hormone (GH)-deficient mice by a single injection of a double-stranded adeno-associated viral vector expressing the GH gene driven by a muscle-specific regulatory cassette. Hum Gene Ther. 2009;20:759\u201366.","journal-title":"Hum Gene Ther"},{"key":"583_CR28","doi-asserted-by":"crossref","unstructured":"Herring SK, Rodgers BD. Murine toxicology assessment of AVGN7.2, a novel gene therapeutic for inclusion body myositis and other muscle wasting diseases. Gene Ther. 2025. (in press).","DOI":"10.1038\/s41434-025-00578-x"},{"key":"583_CR29","doi-asserted-by":"publisher","first-page":"23774","DOI":"10.3390\/ijms141223774","volume":"14","author":"C Stolfi","year":"2013","unstructured":"Stolfi C, Marafini I, De Simone V, Pallone F, Monteleone G. The dual role of Smad7 in the control of cancer growth and metastasis. Int J Mol Sci. 2013;14:23774\u201390.","journal-title":"Int J Mol Sci"},{"key":"583_CR30","doi-asserted-by":"crossref","unstructured":"Troncone E, Monteleone G. Smad7 and colorectal carcinogenesis: a double-edged sword. Cancers 2019;11:612.","DOI":"10.3390\/cancers11050612"},{"key":"583_CR31","unstructured":"Armstrong MJP. Morgan 2022\u2014Sarepta gets another bite at the gene therapy cherry. In: Evaluate vantage. London, U.K.: Evaluate; 2022."},{"key":"583_CR32","unstructured":"Plieth J. Gene therapy trial fails to rectify Sarepta\u2019s sorry record. In: Evaluate vantage. London, U.K.: Evaluate; 2021."},{"key":"583_CR33","unstructured":"Sorrentino T. Sarepta Therapeutics\u2019 SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne. In: Sarepta Therapeutics, Inc., 2021. https:\/\/investorrelations.sarepta.com\/news-releases\/news-release-details\/sarepta-therapeutics-srp-9001-shows-sustained-functional."},{"key":"583_CR34","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1001\/jamaneurol.2020.1484","volume":"77","author":"JR Mendell","year":"2020","unstructured":"Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, et al. Assessment of systemic delivery of rAAVrh74.MHCK7.micro-dystrophin in children with Duchenne muscular dystrophy: a nonrandomized controlled trial. JAMA Neurol. 2020;77:1122\u201331.","journal-title":"JAMA Neurol"},{"key":"583_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.735912","volume":"12","author":"T Markati","year":"2021","unstructured":"Markati T, De Waele L, Schara-Schmidt U, Servais L. Lessons learned from discontinued clinical developments in Duchenne muscular dystrophy. Front Pharm. 2021;12:735912.","journal-title":"Front Pharm"},{"key":"583_CR36","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1038\/d41587-019-00028-1","volume":"37","author":"M Zipkin","year":"2019","unstructured":"Zipkin M. FDA snubs Sarepta\u2019s exon 53-targeting dystrophy drug. Nat Biotechnol. 2019;37:1247\u20138.","journal-title":"Nat Biotechnol"},{"key":"583_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-74192-9","volume":"10","author":"RT Massopust","year":"2020","unstructured":"Massopust RT, Lee YI, Pritchard AL, Nguyen VM, McCreedy DA, Thompson WJ. Lifetime analysis of mdx skeletal muscle reveals a progressive pathology that leads to myofiber loss. Sci Rep. 2020;10:17248.","journal-title":"Sci Rep"},{"key":"583_CR38","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1002\/mus.20920","volume":"37","author":"S Bogdanovich","year":"2008","unstructured":"Bogdanovich S, McNally EM, Khurana TS. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve. 2008;37:308\u201316.","journal-title":"Muscle Nerve"},{"key":"583_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47818-w","volume":"9","author":"RS Pearsall","year":"2019","unstructured":"Pearsall RS, Davies MV, Cannell M, Li J, Widrick J, Mulivor AW, et al. Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease. Sci Rep. 2019;9:11392.","journal-title":"Sci Rep"},{"key":"583_CR40","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1002\/jcsm.12438","volume":"10","author":"P Harish","year":"2019","unstructured":"Harish P, Malerba A, Lu-Nguyen N, Forrest L, Cappellari O, Roth F, et al. Inhibition of myostatin improves muscle atrophy in oculopharyngeal muscular dystrophy (OPMD). J Cachexia Sarcopenia Muscle. 2019;10:1016\u201326.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"583_CR41","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.1152\/ajpendo.00389.2012","volume":"304","author":"JJ Hulmi","year":"2013","unstructured":"Hulmi JJ, Oliveira BM, Silvennoinen M, Hoogaars WM, Ma H, Pierre P, et al. Muscle protein synthesis, mTORC1\/MAPK\/Hippo signaling, and capillary density are altered by blocking of myostatin and activins. Am J Physiol Endocrinol Metab. 2013;304:E41\u201350.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"583_CR42","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/mus.21743","volume":"42","author":"KJ Morine","year":"2010","unstructured":"Morine KJ, Bish LT, Selsby JT, Gazzara JA, Pendrak K, Sleeper MM, et al. Activin IIB receptor blockade attenuates dystrophic pathology in a mouse model of Duchenne muscular dystrophy. Muscle Nerve. 2010;42:722\u201330.","journal-title":"Muscle Nerve"},{"key":"583_CR43","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1096\/fj.201600271RR","volume":"30","author":"N Bechir","year":"2016","unstructured":"Bechir N, Pecchi E, Vilmen C, Le Fur Y, Amthor H, Bernard M, et al. ActRIIB blockade increases force-generating capacity and preserves energy supply in exercising mdx mouse muscle in vivo. FASEB J. 2016;30:3551\u201362.","journal-title":"FASEB J"},{"key":"583_CR44","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1016\/j.ajpath.2010.11.071","volume":"178","author":"EE Pistilli","year":"2011","unstructured":"Pistilli EE, Bogdanovich S, Goncalves MD, Ahima RS, Lachey J, Seehra J, et al. Targeting the activin type IIB receptor to improve muscle mass and function in the mdx mouse model of Duchenne muscular dystrophy. Am J Pathol. 2011;178:1287\u201397.","journal-title":"Am J Pathol"},{"key":"583_CR45","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1096\/fj.04-2796com","volume":"19","author":"S Bogdanovich","year":"2005","unstructured":"Bogdanovich S, Perkins KJ, Krag TO, Whittemore LA, Khurana TS. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. Faseb J. 2005;19:543\u20139.","journal-title":"Faseb J"},{"key":"583_CR46","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1089\/hum.2007.159","volume":"19","author":"C Qiao","year":"2008","unstructured":"Qiao C, Li J, Jiang J, Zhu X, Wang B, Xiao X. Myostatin propeptide gene delivery by adeno-associated virus serotype 8 vectors enhances muscle growth and ameliorates dystrophic phenotypes in mdx mice. Hum Gene Ther. 2008;19:241\u201354.","journal-title":"Hum Gene Ther"},{"key":"583_CR47","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/nature01154","volume":"420","author":"S Bogdanovich","year":"2002","unstructured":"Bogdanovich S, Krag TO, Barton ER, Morris LD, Whittemore LA, Ahima RS, et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature. 2002;420:418\u201321.","journal-title":"Nature"},{"key":"583_CR48","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.ymthe.2005.04.001","volume":"12","author":"S Abmayr","year":"2005","unstructured":"Abmayr S, Gregorevic P, Allen JM, Chamberlain JS. Phenotypic improvement of dystrophic muscles by rAAV\/microdystrophin vectors is augmented by Igf1 codelivery. Mol Ther. 2005;12:441\u201350.","journal-title":"Mol Ther"},{"key":"583_CR49","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1016\/S0002-9440(10)64502-6","volume":"161","author":"P Gregorevic","year":"2002","unstructured":"Gregorevic P, Plant DR, Leeding KS, Bach LA, Lynch GS. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. Am J Pathol. 2002;161:2263\u201372.","journal-title":"Am J Pathol"},{"key":"583_CR50","doi-asserted-by":"crossref","unstructured":"Rodino-Klapac LR, Janssen PM, Shontz KM, Canan B, Montgomery CL, Griffin D, et al. Micro-dystrophin and follistatin co-delivery restores muscle function in aged DMD model. Hum Mol Genet. 2013;22:4929\u201337.","DOI":"10.1093\/hmg\/ddt342"},{"key":"583_CR51","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1093\/hmg\/ddab120","volume":"30","author":"C Xin","year":"2021","unstructured":"Xin C, Chu X, Wei W, Kuang B, Wang Y, Tang Y, et al. Combined gene therapy via VEGF and mini-dystrophin synergistically improves pathologies in temporalis muscle of dystrophin\/utrophin double knockout mice. Hum Mol Genet. 2021;30:1349\u201359.","journal-title":"Hum Mol Genet"},{"key":"583_CR52","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/mt.2009.322","volume":"18","author":"J Dumonceaux","year":"2010","unstructured":"Dumonceaux J, Marie S, Beley C, Trollet C, Vignaud A, Ferry A, et al. Combination of myostatin pathway interference and dystrophin rescue enhances tetanic and specific force in dystrophic mdx mice. Mol Ther. 2010;18:881\u20137.","journal-title":"Mol Ther"},{"key":"583_CR53","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1002\/jcsm.12542","volume":"11","author":"H Zhou","year":"2020","unstructured":"Zhou H, Meng J, Malerba A, Catapano F, Sintusek P, Jarmin S, et al. Myostatin inhibition in combination with antisense oligonucleotide therapy improves outcomes in spinal muscular atrophy. J Cachexia Sarcopenia Muscle. 2020;11:768\u201382.","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"583_CR54","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1002\/mus.25268","volume":"55","author":"C Campbell","year":"2017","unstructured":"Campbell C, McMillan HJ, Mah JK, Tarnopolsky M, Selby K, McClure T, et al. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial. Muscle Nerve. 2017;55:458\u201364.","journal-title":"Muscle Nerve"},{"key":"583_CR55","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1111\/cen.13601","volume":"88","author":"T Garito","year":"2018","unstructured":"Garito T, Zakaria M, Papanicolaou DA, Li Y, Pinot P, Petricoul O, et al. Effects of bimagrumab, an activin receptor type II inhibitor, on pituitary neurohormonal axes. Clin Endocrinol. 2018;88:908\u201319.","journal-title":"Clin Endocrinol"},{"key":"583_CR56","doi-asserted-by":"publisher","first-page":"E1036","DOI":"10.1152\/ajpendo.00001.2019","volume":"316","author":"W Czaja","year":"2019","unstructured":"Czaja W, Nakamura YK, Li N, Eldridge JA, DeAvila DM, Thompson TB, et al. Myostatin regulates pituitary development and hepatic IGF1. Am J Physiol Endocrinol Metab. 2019;316:E1036\u201349.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"583_CR57","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1093\/nar\/15.3.1281","volume":"15","author":"PM Sharp","year":"1987","unstructured":"Sharp PM, Li WH. The codon Adaptation Index-a measure of directional synonymous codon usage bias, and its potential applications. Nucleic Acids Res. 1987;15:1281\u201395.","journal-title":"Nucleic Acids Res"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00583-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00583-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00583-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T00:06:19Z","timestamp":1771977979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-025-00583-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":57,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["583"],"URL":"https:\/\/doi.org\/10.1038\/s41434-025-00583-0","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"assertion":[{"value":"5 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BDR is the majority owner, Founder and CEO of Aavogen, which is developing AVGN7.2 for the treatment of different myopathies, muscular dystrophies and other muscle wasting disorders. CWW is the Co-founder and CSO of Myologica LLC, a privately owned contract research organization that performed many of the studies reported herein.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Animal experiments were performed by Myologica LLC in leased vivarium and laboratory space at the University of Maryland Baltimore. Mice were housed in environmentally controlled rooms and provided food and water\n                      ad libitum\n                      . Housing and use were conducted in accordance to animal use protocols preapproved by the university\u2019s institutional animal care and use committee and according to National Institutes of Health guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}